AssetMark Inc
TLX

AssetMark Inc’s Telix Pharmaceuticals TLX Stock Holding History

AssetMark Inc’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.46K Buy
153
+108
+240% +$823 ﹤0.01% 2949
2025
Q4 		$337 Buy
45
+4
+10% +$38 ﹤0.01% 3172
2025
Q3 		$392 Buy
41
+23
+128% +$282 ﹤0.01% 2970
2025
Q2 		$289 Buy
+18
New +$302 ﹤0.01% 2825

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $6.97B AUM 29.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

AssetMark Inc's TLX Position: Q1 2026 in Review

AssetMark Inc increased its Telix Pharmaceuticals (TLX) stake by 240% in Q1 2026, buying an estimated $823 and bringing the position to 153 shares worth $1.46K. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

AssetMark Inc first reported a position in TLX in Q2 2025 and has held it in 4 quarters since. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • AssetMark Inc held 153 shares of Telix Pharmaceuticals worth $1.46K as of Q1 2026.
  • AssetMark Inc bought 108 Telix Pharmaceuticals shares in Q1 2026, an estimated $823.
  • Telix Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #2949 holding.
  • AssetMark Inc first reported a position in Telix Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.